[1]Bruniera FR, Ferreira FM, Saviolli LR, et al. The use of vancomycin with its therapeutic and adverse effects: a review[J]. Eur Rev Med Pharmacol Sci, 2015, 19(4): 694-700.
[2]Ye ZK, Tang HL, Zhai SD. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis [J]. PLoS One, 2013, 8(10): e77169.
[3]Li X, Sun S, Ling X, et al. Plasma and cerebrospinal fluid population pharmacokinetics of vancomycin in postoperative neurosurgical patients after combined intravenous and intraventricular administration [J]. Eur J Clin Pharmacol, 2017, 73(12): 1599-1607.
[4]Seehusen DA, Reeves MM, Fomin DA. Cerebrospinal fluid analysis [J]. Am Fam Physician, 2003, 68(6): 1103-1108.
[5]Sullins akabdel-rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents [J]. Paediatr Drugs, 2013, 15(2): 93-117.
[6]Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients [J]. Surg Neurol, 2008, 69(2): 126-128; discussion 129.
[7]Drew RJ, Cole TS, Lee MK, et al. Antimicrobial treatment options for neurosurgical ventricular shunt infections in children from 1993 to 2012: a systematic review [J]. Childs Nerv Syst, 2014, 30(5): 841-850.
[8]NgK, Mabasa VH, Chow I, et al. Systematic review of efficacy, pharmacokinetics, and administration of intraventricular vancomycin in adults [J]. Neurocrit Care, 2014, 20(1): 158-171.
[9]Li X, Wu Y, Sun S, et al. Population pharmacokinetics of vancomycin in postoperative neurosurgical patients and the application in dosing recommendation[J]. J Pharm Sci, 2016, 105: 3425-3431. |